Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Reprod Biomed Online ; 8(1): 115-8, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14759299

ABSTRACT

To date, limited data exist concerning the relation between endometrial thickness on the day of human chorionic gonadotrohin (HCG) administration and ongoing pregnancy achievement in cycles stimulated with clomiphene citrate for intrauterine insemination (IUI). In a prospective study, 168 couples were stimulated with clomiphene citrate from day 3 to day 7 of the cycle and endometrial thickness was assessed by ultrasound three times on the day of ovulation triggering. Ovulation was induced with HCG as soon as >/=1 follicle of >/=17 mm was present at ultrasound independently of endometrial thickness. IUI was performed 36 h after HCG administration. The main outcome measure was ongoing pregnancy. No difference was observed in endometrial thickness between patients who did or did not achieve an ongoing pregnancy (7.6 +/- 0.3 versus 7.6 +/- 0.2 respectively; P = 0.7). No discriminative ability of endometrial thickness on the achievement of ongoing pregnancy could be shown by receiver operating characteristic (ROC) curve analysis (area under the ROC curve 0.51, 95% CI: 0.44-0.59). In conclusion, endometrial thickness cannot predict ongoing pregnancy achievement in IUI cycles stimulated with clomiphene citrate.


Subject(s)
Clomiphene/therapeutic use , Endometrium/diagnostic imaging , Fertility Agents, Female/therapeutic use , Infertility, Female/diagnostic imaging , Infertility, Female/therapy , Insemination, Artificial , Menstrual Cycle , Ovulation Induction , Adult , Chorionic Gonadotropin/therapeutic use , Female , Humans , Pregnancy , Pregnancy Rate , Prognosis , Prospective Studies , ROC Curve , Ultrasonography
2.
Hum Reprod ; 17(12): 3079-83, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12456606

ABSTRACT

BACKGROUND: Misoprostol is a prostaglandin E(1) analogue that has been used for medical abortion. We conducted this prospective study to compare the efficacy of vaginal misoprostol for abortion in women at a gestational age of <42 days and in women at a gestational age of 42-56 days. METHODS: A total of 160 women seeking medical termination of a pregnancy of <56 days were enrolled in the study. Medical termination was performed using 800 micro g of vaginal misoprostol, repeated every 24 h for a maximum of three doses. RESULTS: The overall complete abortion rate was 91.3%. In group A (gestation <42 days) complete abortion occurred in 96.3% of women, whereas in group B (gestation = 42-56 days) complete abortion occurred in 86.3% of women (P < 0.025). The two groups did not differ significantly with respect to side-effects (incidence of pain, bleeding, nausea, diarrhoea, fever and headache). Women who had aborted successfully were significantly more satisfied with the method compared with women who did not (P < 0.001). CONCLUSIONS: The vaginal misoprostol-alone regimen is highly effective for women seeking medical abortion of pregnancies of

Subject(s)
Abortifacient Agents, Nonsteroidal/administration & dosage , Abortion, Induced , Gestational Age , Misoprostol/administration & dosage , Abortifacient Agents, Nonsteroidal/adverse effects , Administration, Intravaginal , Adolescent , Adult , Diarrhea , Female , Fever , Headache , Humans , Misoprostol/adverse effects , Nausea , Pain , Patient Satisfaction , Pregnancy , Treatment Outcome , Uterine Hemorrhage
SELECTION OF CITATIONS
SEARCH DETAIL
...